Research
Hormonal
In patients with type 2 diabetes and established cardiovascular disease, GLP-1 receptor agonists or SGLT2 inhibitors with demonstrated cardiovascular benefit are recommended when glycemic goals are not achieved with metformin.
Practitioners should consider GLP-1 receptor agonists or SGLT2 inhibitors for patients with type 2 diabetes who have cardiovascular disease and are not meeting glycemic targets with metformin.
StrongSupportsmedium confidence
agents from the GLP-1 receptor agonist or SGLT2 inhibitor classes with demonstrated cardiovascular benefit constitute the recommended treatment.
Why this rating
The claim is based on established treatment guidelines for a specific patient population.
Source
Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Rita R. Kalyani · New England Journal of Medicine · 2021
otherCited 92×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →